Biogen
The latest news about Biogen: headlines, AI summaries and the full story from every source.
- Biogen's Litifilimab Shows Positive Long-Term Results in Cutaneous Lupus Trial
- Biogen Acquires RayThera to Bolster Immunology Portfolio Amid Shifting Financial Dynamics
- Biogen Reports Q2 Revenue Growth Driven by Strong Performance of Growth Portfolio
- Biogen Shares Drop Following Mid-Stage Trial Results for Alzheimer’s Drug
- FDA Approves Subcutaneous Version of Biogen and Eisai's Alzheimer's Treatment Leqembi
- Truist Upgrades Biogen to Buy Ahead of Alzheimer's Drug Data
- Pomerantz Law Firm Investigates Biogen Inc. for Potential Securities Fraud
- Biogen Faces Securities Investigation by Pomerantz Law Firm Following Disappointing Alzheimer's Drug Trial Results
- Biogen Reports Strong Q1 Earnings Despite Guidance Cut
- Biogen Reports Strong Earnings and Revenue Growth, Driving Stock Higher
- Biogen Reports Q3 2024 Earnings with Revenue Decline and Mixed Performance Across Products
- Biogen Reports Q2 2025 Earnings with Revenue Growth and EPS Increase
- Biogen (BIIB) Q3 2025 Earnings Call Transcript Released
- Wells Fargo Upgrades Biogen to Overweight Amid Confidence in New Pipeline Programs
- Biogen's Long-Term Performance and Uncertain Future